1.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0305091, WYETH-C-3066K1-304-WW, NCT00065468
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3066K1-305, NCT00117598
|
|
3.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NABTC-0101, NCT00022724, NABTC-01-01
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NABTC-0402, NCI-06-C-0053, NABTC-04-02, NCT00112736
|
|
5.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-000606401, GENE-C9940-32, UCLA-CCI-779, W-AR-3066K1-201-US, NCI-G01-1917, NCT00012142
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N997B, N997B, NCT00016328
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CHNMC-PHII-27, CHNMC-IRB-99167, NCI-29, NCT00022464, 29
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1500, NCT00028028, E1500
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0186, N0186, NCT00033267
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CWRU-080234, CWRU-WAGM01102, WYETH-C-3066A1-204-WW, NCT00061971
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-0306091, WYETH-C-3066A1-132-US, NCT00071968
|
|
12.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CAN-NCIC-IND160, NCT00072176, NCIC-160, IND160
|
|
13.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MDA-2003-0530, NCI-6182, NCT00075647, 6182
|
|
14.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N0323, N0323, NCT00079235
|
|
15.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: OSU-0347, NCI-6186, OSU-2003C0090, 6186, NCT00079456
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-12983A, NCI-6199, 6199, NCT00084474
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI
Protocol IDs: MDA-2003-0830, 6178, NCI-6178, NCT00084916
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: NCI
Protocol IDs: MDA-2003-0886, NCI-6177, 6177, NCT00086840
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MAYO-MC027B, 6156, NCI-6156, NCT00087074
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: PMH-PHL-021, NCI-6171, 6171, NCT00093782
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N038H, N038H, NCT00109967
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: SWOG-S0438, S0438, NCT00281957
|
|
23.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-14705A, 7674, NCI-7674, NCT00376688
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: NCI
Protocol IDs: GOG-0170I, NCT00429793
|
|
25.
|
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3066K1-2217, NCT00494091
|
